DHEA for Menopause: a look at benefits and dosing - Felice Gersh, MD

Why DHEA Matters During and After Menopause

Menopause is a hormonal seismic shift. Most of the attention goes to estrogen and progesterone, and rightly so, since those are the hormones whose sudden decline drives the hot flashes, sleep disruption, mood changes, and metabolic shifts that define the menopausal transition. But DHEA often gets left out of the conversation, and according to this discussion with Dr. Felice Gersh, that is a significant oversight. DHEA plays a role in menopausal health that is both independent of and complementary to estrogen and progesterone, and understanding how to use it properly can make a real difference.

By the time a woman reaches menopause, her DHEA levels have already been declining for two decades or more. The adrenal glands, which are the primary source of DHEA in post-menopausal women (since ovarian production drops dramatically), continue producing it but at progressively lower levels. This creates a compounding effect: you lose your primary sex hormones at menopause while simultaneously running on depleted precursor hormones. The result is a deeper hormonal deficit than most women realize.

DHEA is a reservoir that tissues throughout the body can convert into estrogen and testosterone locally. This is called intracrinology, the process by which cells make their own hormones from circulating precursors. In post-menopausal women, this local conversion becomes the primary way many tissues get the hormonal support they need, since systemic estrogen and testosterone have dropped to minimal levels. When DHEA is also low, even this backup system is compromised.

Vaginal and Urogenital Health: Where DHEA Shines Brightest

The most robust evidence for DHEA in menopause is for vaginal health. Genitourinary syndrome of menopause (GSM), which includes vaginal dryness, irritation, pain during intercourse, and urinary symptoms, affects the majority of post-menopausal women and often worsens over time because the vaginal tissue depends heavily on estrogen for maintaining its thickness, moisture, and pH. Without estrogen, the tissue atrophies progressively.

Intravaginal DHEA (prasterone, sold as Intrarosa) is FDA-approved for treating moderate to severe dyspareunia (painful intercourse) associated with menopause. The mechanism is elegant: the vaginal tissue contains the enzymes needed to convert DHEA into estradiol and testosterone locally, providing hormonal support right where it is needed without significantly raising systemic hormone levels. This is a meaningful advantage for women who cannot or prefer not to use systemic hormone therapy.

Clinical trials showed significant improvements in vaginal dryness, pain with intercourse, and vaginal pH with daily intravaginal DHEA use. The systemic absorption is minimal, which addresses one of the primary concerns women and their doctors have about vaginal hormonal therapies. Blood levels of estrogen and testosterone remained within the post-menopausal range in most studies, making it a option even for women with a history of hormone-sensitive breast cancer, though oncologist guidance is still recommended in those cases.

Beyond Vaginal Health: Systemic Benefits

Dr. Gersh discusses the broader potential of oral DHEA supplementation for post-menopausal women, and this is where the evidence becomes more nuanced. Some studies suggest improvements in bone density with oral DHEA, particularly when combined with calcium and vitamin D. The mechanism is thought to involve both the androgenic and estrogenic metabolites of DHEA stimulating bone-forming cells while reducing bone resorption.

There is also research pointing to mood and cognitive benefits. DHEA has neurosteroid properties, meaning it acts directly on the brain independent of its conversion to sex hormones. It modulates GABA and NMDA receptors, and some studies have found antidepressant effects, particularly in people with low baseline DHEA levels. For post-menopausal women dealing with mood changes and cognitive fog, this is an area worth exploring, though the evidence is not strong enough to consider DHEA a primary treatment for depression or cognitive decline.

Skin quality is another area of interest. DHEA contributes to sebum production and collagen maintenance, both of which decline with menopause. Some women report improvements in skin thickness, moisture, and overall appearance with DHEA supplementation, though formal studies on this outcome are limited.

Dosing Strategies for Menopausal Women

Dosing DHEA in menopausal women requires a different approach than what many supplement labels suggest. The standard over-the-counter dose of 25-50 mg may be too high for many women, particularly those who are lean or have high enzyme activity for androgen conversion. Dr. Gersh recommends starting at lower doses, typically 5-15 mg for systemic oral use, and adjusting based on bloodwork.

For intravaginal use, the standard Intrarosa dose is 6.5 mg inserted nightly. This dose was established through clinical trials and represents the amount that produces local benefit with minimal systemic absorption. Women who are using the over-the-counter oral form intravaginally (a common off-label practice) should work with their provider to determine appropriate dosing, as compounding pharmacies can prepare vaginal suppositories at specific doses.

Monitoring should include DHEA-S, testosterone (total and free), estradiol, and SHBG at baseline and 6-8 weeks after starting supplementation. The goal is to raise DHEA-S into a range appropriate for a pre-menopausal woman (roughly 150-350 mcg/dL) while keeping testosterone and estradiol within ranges that do not produce unwanted side effects.

Signs Your Dose Is Too High

Because women are more sensitive to androgenic effects than men, signs of excessive DHEA conversion to androgens deserve attention. Oily skin and acne are often the first indicators, followed by increased facial or body hair growth, scalp hair thinning, and irritability. If any of these appear, the dose should be reduced before the effects become more pronounced.

On the estrogen side, breast tenderness and bloating can indicate excessive conversion to estradiol. While this is less common with the low doses typically used in menopausal women, it can occur in women with higher body fat (since fat tissue contains aromatase, the enzyme that converts androgens to estrogens).

DHEA as Part of a Thorough Menopausal Strategy

DHEA should not be viewed in isolation. For most menopausal women, it works best as part of a broader approach that may include estrogen, progesterone, testosterone, and lifestyle modifications. Dr. Gersh emphasizes that DHEA is a complement to, not a replacement for, thorough hormone therapy when that is indicated. A woman with severe vasomotor symptoms (hot flashes, night sweats) needs estrogen. DHEA alone will not address those symptoms adequately.

Where DHEA adds the most value is in filling the gaps that standard HRT may not cover. Vaginal health, adrenal support, neurosteroid effects on mood and cognition, and providing the raw material for local tissue hormone production are areas where DHEA has a role that estrogen and progesterone alone may not fully address.

The conversation about DHEA in menopause is still evolving, and more high-quality research would be welcome. But for women who are working with informed practitioners and willing to monitor their bloodwork, DHEA represents a tool that is evidence-supported, reasonably safe at appropriate doses, and capable of addressing aspects of menopausal health that other therapies may miss.

The Research Space and What Still Needs Answers

The research on DHEA in menopause has grown substantially over the past two decades, but significant gaps remain. Most studies have been relatively short-term (6-12 months), and long-term safety data beyond 2-3 years is limited. For a therapy that many women may use for decades during the post-menopausal period, this is a meaningful limitation that both patients and practitioners should acknowledge.

The cognitive benefits of DHEA in menopausal women are perhaps the most exciting but least well-established area. Neurosteroid activity is well-documented in animal models, and small human studies have shown improvements in mood and cognitive markers, but large randomized controlled trials specifically in menopausal women are lacking. Given the scale of the dementia and cognitive decline problem in aging populations, research funding in this area would be well justified.

Sexual function is another domain where DHEA shows promise beyond vaginal health. Some studies have found improvements in desire, arousal, and satisfaction with both oral and intravaginal DHEA, which makes sense given that testosterone (a downstream product of DHEA) plays a significant role in female sexual function. For women who are reluctant to use testosterone directly, DHEA offers an indirect approach to supporting androgenic function.

The individualized nature of DHEA metabolism means that population-level study results may not fully capture the benefit or risk for any specific woman. Two women taking the same dose can have very different downstream hormonal profiles based on their enzyme genetics, body composition, and existing hormonal milieu. This reality reinforces the importance of personalized monitoring and adjustment rather than following a one-size-fits-all dosing protocol. The investment in regular bloodwork pays for itself in optimization accuracy and risk reduction.

For practitioners looking to incorporate DHEA into menopausal care, starting with the intravaginal route for GSM symptoms has the strongest evidence base and the lowest systemic risk. Oral DHEA for broader systemic benefits is reasonable as a second step for women who have confirmed low DHEA-S levels and specific symptoms that are not fully addressed by standard HRT. The key is building the protocol incrementally, monitoring at each step, and maintaining open communication about both expected benefits and realistic limitations.

The conversation about DHEA in menopause ultimately reflects a broader shift in how women's health is approached: moving from a one-size-fits-all model to personalized, hormone-informed care that recognizes the full complexity of the endocrine system. DHEA is one tool in that toolkit, and when used thoughtfully alongside thorough hormone evaluation and lifestyle optimization, it addresses dimensions of menopausal health that other therapies may not fully reach.